The Enterprise Value as of November 2024 (TTM) for Immuneering Corporation (IMRX) is 4.26B

According to Immuneering Corporation’s latest financial reports and current stock price. The company's current Enterprise Value is 4.26B. This represents a change of 284.88% compared to the average of 1.11B of the last 4 quarters.

Immuneering Corporation (IMRX) Historical Enterprise Value (quarterly & annually)

How has IMRX Enterprise Value performed in the past?

The mean historical Enterprise Value of Immuneering Corporation over the last ten years is 286.83M. The current 4.26B Enterprise Value has changed 148.46% with respect to the historical average. Over the past ten years (40 quarters), IMRX's Enterprise Value was at its highest in in the September 2024 quarter at 4.27B. The Enterprise Value was at its lowest in in the June 2024 quarter at -20722016.65.

Immuneering Corporation (IMRX) Enterprise Value by Quarter and Year

Discovering the peaks and valleys of Immuneering Corporation Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Immuneering Corporation (IMRX) Average Enterprise Value

How has IMRX Enterprise Value performed in the past?

The current Enterprise Value of Immuneering Corporation (IMRX) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

Immuneering Corporation (IMRX) Enterprise Value vs. Peers

How is IMRX’s Enterprise Value compared to its peers?

Immuneering Corporation’s Enterprise Value is greater than Theseus Pharmaceuticals, Inc. (138.26M), greater than PMV Pharmaceuticals, Inc. (47.77M), greater than Cullinan Oncology, Inc. (630.54M), greater than Enliven Therapeutics, Inc. (1.10B), greater than Larimar Therapeutics, Inc. (363.34M), greater than Centessa Pharmaceuticals plc (1.75B), greater than Celcuity Inc. (574.33M), greater than Ikena Oncology, Inc. (45.73M), greater than Replimune Group, Inc. (984.10M), greater than Nuvectis Pharma, Inc. (81.37M), greater than Lyra Therapeutics, Inc. (23.90M), greater than Kronos Bio, Inc. (5.32M), greater than Gossamer Bio, Inc. (331.04M), greater than Monte Rosa Therapeutics, Inc. (439.72M), greater than NewAmsterdam Pharma Company N.V. (1.37B), greater than Inventiva S.A. (228.20M), greater than Compass Therapeutics, Inc. (182.75M),

Build a custom stock screener for Immuneering Corporation (IMRX) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Immuneering Corporation using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Immuneering Corporation (IMRX) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Immuneering Corporation or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.